Market revenue in 2023 | USD 27.1 million |
Market revenue in 2030 | USD 33.9 million |
Growth rate | 3.3% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.36% in 2023. Horizon Databook has segmented the UAE point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Being a high-income country, the UAE government aims to provide universal access to updated and advanced healthcare services by 2021. Due to its vast financial resources and adequate government funding, the point-of-care molecular diagnostics market in UAE is likely to progress steadily. The increasing prevalence of chronic diseases is one of the major factors fueling the growth in the UAE market.
According to World Life Expectancy, CVD, stroke, diabetes, and COPD were some of the major causes of death in the country in 2020. It is also observed that nearly 23.4% to 24.7% of men smoke cigarettes in this country, which further increases the risk of lung & cardiovascular diseases, boosting the demand for testing. In addition, the presence of laboratories conducting point-of-care molecular diagnostics tests for infectious diseases is expected to boost market growth.
For instance, National Reference Laboratory conducts molecular diagnosis using RT-PCR for human papillomavirus, hepatitis, Sexually Transmitted Infections (STIs), HIV, and other infectious diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UAE point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account